254 related articles for article (PubMed ID: 20138954)
21. Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
Shioda K; Nisijima K; Yoshino T; Kuboshima K; Iwamura T; Yui K; Kato S
Neurotoxicology; 2008 Nov; 29(6):1030-6. PubMed ID: 18722468
[TBL] [Abstract][Full Text] [Related]
22. Blockade of noradrenaline transport abolishes 4-methylthioamphetamine-induced contraction of the rat aorta in vitro.
Quinn ST; Guiry PJ; Schwab T; Keenan AK; McBean GJ
Auton Autacoid Pharmacol; 2006 Oct; 26(4):335-44. PubMed ID: 16968472
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency.
Cardoso CM; Custódio JB; Almeida LM; Moreno AJ
Toxicol Appl Pharmacol; 2001 Nov; 176(3):145-52. PubMed ID: 11714246
[TBL] [Abstract][Full Text] [Related]
24. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide.
Freezer A; Salem A; Irvine RJ
Brain Res; 2005 Apr; 1041(1):48-55. PubMed ID: 15804499
[TBL] [Abstract][Full Text] [Related]
25. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates.
Carvalho M; Milhazes N; Remião F; Borges F; Fernandes E; Amado F; Monks TJ; Carvalho F; Bastos ML
Arch Toxicol; 2004 Jan; 78(1):16-24. PubMed ID: 14586543
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat.
Puerta E; Hervias I; Goñi-Allo B; Lasheras B; Jordan J; Aguirre N
J Neurochem; 2009 Feb; 108(3):755-66. PubMed ID: 19187094
[TBL] [Abstract][Full Text] [Related]
27. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
28. Metabolic interactions between ethanol and MDMA in primary cultured rat hepatocytes.
Pontes H; de Pinho PG; Fernandes E; Branco PS; Ferreira LM; Carmo H; Remião F; Carvalho F; Bastos ML
Toxicology; 2010 Apr; 270(2-3):150-7. PubMed ID: 20170704
[TBL] [Abstract][Full Text] [Related]
29. Disruption of hepatic mitochondrial bioenergetics is not a primary mechanism for the toxicity of methoprene - relevance for toxicological assessment.
Monteiro JP; Oliveira PJ; Moreno AJ; Jurado AS
Chemosphere; 2008 Jul; 72(9):1347-54. PubMed ID: 18511104
[TBL] [Abstract][Full Text] [Related]
30. Tyramine and monoamine oxidase inhibitors as modulators of the mitochondrial membrane permeability transition.
Marcocci L; De Marchi U; Salvi M; Milella ZG; Nocera S; Agostinelli E; Mondovi B; Toninello A
J Membr Biol; 2002 Jul; 188(1):23-31. PubMed ID: 12172644
[TBL] [Abstract][Full Text] [Related]
31. Acute administration of 3,4-methylenedioxymethamphetamine (MDMA) induces oxidative stress, lipoperoxidation and TNFα-mediated apoptosis in rat liver.
Cerretani D; Bello S; Cantatore S; Fiaschi AI; Montefrancesco G; Neri M; Pomara C; Riezzo I; Fiore C; Bonsignore A; Turillazzi E; Fineschi V
Pharmacol Res; 2011 Nov; 64(5):517-27. PubMed ID: 21864684
[TBL] [Abstract][Full Text] [Related]
32. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation.
Berson A; Descatoire V; Sutton A; Fau D; Maulny B; Vadrot N; Feldmann G; Berthon B; Tordjmann T; Pessayre D
J Pharmacol Exp Ther; 2001 Nov; 299(2):793-800. PubMed ID: 11602696
[TBL] [Abstract][Full Text] [Related]
33. N-Nitrosofenfluramine induces cytotoxicity via mitochondrial dysfunction and oxidative stress in isolated rat hepatocytes.
Nakagawa Y; Suzuki T; Kamimura H; Nagai F
Arch Toxicol; 2005 Jun; 79(6):312-20. PubMed ID: 15696257
[TBL] [Abstract][Full Text] [Related]
34. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
35. Effects of isocoumarins isolated from Paepalanthus bromelioides on mitochondria: uncoupling, and induction/inhibition of mitochondrial permeability transition.
Cálgaro-Helena AF; Devienne KF; Rodrigues T; Dorta DJ; Raddi MS; Vilegas W; Uyemura SA; Santos AC; Curti C
Chem Biol Interact; 2006 Jun; 161(2):155-64. PubMed ID: 16716282
[TBL] [Abstract][Full Text] [Related]
36. Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion.
Farah R; Farah R
Pediatr Emerg Care; 2008 Sep; 24(9):615-7. PubMed ID: 18797371
[TBL] [Abstract][Full Text] [Related]
37. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
38. Aroclor 1254 induced cytotoxicity and mitochondrial dysfunction in isolated rat hepatocytes.
Aly HA; Domènech O
Toxicology; 2009 Aug; 262(3):175-83. PubMed ID: 19486918
[TBL] [Abstract][Full Text] [Related]
39. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.
Biezonski DK; Meyer JS
J Neurochem; 2010 Feb; 112(4):951-62. PubMed ID: 20002520
[TBL] [Abstract][Full Text] [Related]
40. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
